Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Dose-Ranging, Double Blind Study to Demonstrate the Safety and Efficacy of a CITI-002 Cream in the Seven Day Twice-Daily Treatment of Grade II or III Hemorrhoids

Next Previous
Trial Profile

A Randomized, Dose-Ranging, Double Blind Study to Demonstrate the Safety and Efficacy of a CITI-002 Cream in the Seven Day Twice-Daily Treatment of Grade II or III Hemorrhoids

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 03 Jan 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Halobetasol/Lidocaine (Primary) ; Lidocaine; Ulobetasol
  • Indications Haemorrhoids
  • Focus Therapeutic Use
  • Sponsors Citius Pharmaceuticals Inc

Most Recent Events

  • 02 Jan 2024 According to a Citius Pharmaceuticals media release, in early 2024, the company plans to meet with the FDA to discuss the results of the trial and next steps in the Halo-Lido program.
  • 14 Aug 2023 According to a Citius Pharmaceuticals media release, company expecting research and development expenses will stabilize in fiscal 2023 as focus is on the commercialization of LYMPHIR and complete Phase 3 trial for Mino-Lok and Phase 2b trial for Halo-Lido.
  • 14 Aug 2023 According to a Citius Pharmaceuticals Inc media release, R&D expenses were $3.8 million and $11.9 million for the three and nine months ended June 30, 2023, respectively, compared to $4.9 million and $13.8 million for the comparable periods ended June 30, 2022. The decrease reflects lower Mino-Lok and LYMPHIR trial costs offset by higher Halo-Lido Phase 2b study costs as the trial was completed during the three months ended June 30, 2023.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top